Recent studies have indicated that TSHR plays a critical role in the progression of thyroid cancer and may serve as a key target for the treatment of residual or metastatic thyroid cancers, particularly radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). This evidence concerns the gene TSHR and thyroid gland carcinoma.